Urothelial carcinoma: S100P and GATA3

Reference 1

Polyclonal anti-S100P, S0084

% positive (number of cases studied), nuclear with or without cytoplasmic

monoclonal S100P

% positive (number of cases studied), nuclear with or without cytoplasmic

GATA3

% positive (number of cases studied)

Renal urothelial

94% of 17

80% of 15

67% of 15

Bladder urothelial, high grade

81% of 215

71% of 219

57% of 226

Bladder urothelial, low grade

100% of 80

96% of 81

95% of 82

Bladder urothelial, all

86% of 295 (strongly positive in 78% of cases)

78% of 300 (strongly positive in 62% of cases)

67% of 308

Bladder, squamous cell

0 of 7

0 of 7

0 of 7

Stomach

58% of 19

62% of 21

0 of 15

Oesophageal adenocarcinoma

4 of 4

3 of 5

0 of 4

Oesophageal squamous

0 of 7

0 of 8

0 of 8

Pancreatic

4 of 6

3 of 10

0 of 6

Colorectal

61% of 72

20% of 80

0 of 71

Hepatocellular

36% of 11

14% of 14

0 of 13

Lung

27% of 41

10% of 48

0 of 45

Ovary

15% of 40

7% of 41

0 of 39

Prostate

3% of 260

2% of 256

0 of 257

Adrenal

0 of 3

0 of 3

0 of 3

Breast ductal

1 of 4

0 of 4

4 of 4

Cervical adenocarcinoma

1 of 4

0 of 5

0 of 4

Cervical squamous

2 of 4

0 of 6

0 of 6

Endometrial

7% of 30

0 of 31

0 of 27

Gallbladder

0 of 1

0 of 1

0 of 1

Melanoma

0 of 13

0 of 16

0 of 12

Renal clear cell

1% of 125

0 of 125

0 of 111

Renal papillary

0 of 9

0 of 9

0 of 9

Renal chromophobe

0 of 12

0 of 12

0 of 11

Renal sarcomatoid

0 of 2

0 of 2

0 of 2

Seminoma

0 of 10

0 of 10

0 of 6

Squamous NOS

19% of 16

0 of 20

0 of 23

Thyroid

0 of 14

0 of 17

0 of 18

The monoclonal antibody has greater specificity for urothelial neoplasms, at the expense of lower sensitivity¹.

p63 and CK5/6 were studied on the same cases:

p63

CK5/6

urothelial carcinoma

87% of 292 cases (80% of the total were strongly positive)

54% of 293 cases (22% of the total were strongly positive)

renal cell carcinoma

0 of 117 cases

7 of 131 cases

prostatic carcinoma

1 of 251 cases

11 of 254

References

¹Higgins JP, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol 2007; 31:673-80

This page last revised 30.5.2007.

Reference 1	Polyclonal anti-S100P, S0084 % positive (number of cases studied), nuclear with or without cytoplasmic	monoclonal S100P % positive (number of cases studied), nuclear with or without cytoplasmic	GATA3 % positive (number of cases studied)
Renal urothelial	94% of 17	80% of 15	67% of 15
Bladder urothelial, high grade	81% of 215	71% of 219	57% of 226
Bladder urothelial, low grade	100% of 80	96% of 81	95% of 82
Bladder urothelial, all	86% of 295 (strongly positive in 78% of cases)	78% of 300 (strongly positive in 62% of cases)	67% of 308
Bladder, squamous cell	0 of 7	0 of 7	0 of 7
Stomach	58% of 19	62% of 21	0 of 15
Oesophageal adenocarcinoma	4 of 4	3 of 5	0 of 4
Oesophageal squamous	0 of 7	0 of 8	0 of 8
Pancreatic	4 of 6	3 of 10	0 of 6
Colorectal	61% of 72	20% of 80	0 of 71
Hepatocellular	36% of 11	14% of 14	0 of 13
Lung	27% of 41	10% of 48	0 of 45
Ovary	15% of 40	7% of 41	0 of 39
Prostate	3% of 260	2% of 256	0 of 257
Adrenal	0 of 3	0 of 3	0 of 3
Breast ductal	1 of 4	0 of 4	4 of 4
Cervical adenocarcinoma	1 of 4	0 of 5	0 of 4
Cervical squamous	2 of 4	0 of 6	0 of 6
Endometrial	7% of 30	0 of 31	0 of 27
Gallbladder	0 of 1	0 of 1	0 of 1
Melanoma	0 of 13	0 of 16	0 of 12
Renal clear cell	1% of 125	0 of 125	0 of 111
Renal papillary	0 of 9	0 of 9	0 of 9
Renal chromophobe	0 of 12	0 of 12	0 of 11
Renal sarcomatoid	0 of 2	0 of 2	0 of 2
Seminoma	0 of 10	0 of 10	0 of 6
Squamous NOS	19% of 16	0 of 20	0 of 23
Thyroid	0 of 14	0 of 17	0 of 18

	p63	CK5/6
urothelial carcinoma	87% of 292 cases (80% of the total were strongly positive)	54% of 293 cases (22% of the total were strongly positive)
renal cell carcinoma	0 of 117 cases	7 of 131 cases
prostatic carcinoma	1 of 251 cases	11 of 254